Both deleterious modifiers and salutary modifiers of AIC can be identified by using a forward mutagenesis screening approach. While GBT0002/sorbs2b, GBT0136/ano5a, and GBT0411/dnajb6b(L) were identified as deleterious modifiers, GBT0419/rxraa was identified as a salutary modifier. Mechanistic studies of GBT0411/dnajb6b(L) identified Tg(dnajb6b(L)) that exerts salutary modifying effects on AIC (86).

Two time-dependent therapeutic avenues have been suggested for aAIC. While RA agonist have been identified to exert therapeutic effects at the early phase of aAIC, autophagy activators have been identified to exert therapeutic effects at the later phase of aAIC (67).